4.3 Article

Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells

期刊

ONCOTARGET
卷 5, 期 13, 页码 4895-4908

出版社

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.2052

关键词

CXCL8; CCL2; CXCL12; CXCR4; prostate cancer; PTEN

资金

  1. Cancer Research UK [C11512/A11825, C212/A11342]
  2. Medical Research Council [MR/J007641/1]
  3. McClay Foundation
  4. Friends of the Cancer Centre
  5. Medical Research Council [MR/J007641/1] Funding Source: researchfish
  6. MRC [MR/J007641/1] Funding Source: UKRI

向作者/读者索取更多资源

Impaired PTEN function is a genetic hallmark of aggressive prostate cancers (CaP) and is associated with increased CXCL8 expression and signaling. The current aim was to further characterize biological responses and mechanisms underpinning CXCL8-promoted progression of PTEN-depleted prostate cancer, focusing on characterizing the potential interplay between CXCL8 and other disease-promoting chemokines resident within the prostate tumor microenvironment. Autocrine CXCL8-stimulation (i) increased expression of CXCR1 and CXCR2 in PTEN-deficient CaP cells suggesting a self-potentiating signaling axis and (ii) induced expression of CXCR4 and CCR2 in PTEN-wild-type and PTEN-depleted CaP cells. In contrast, paracrine CXCL8 signaling induced expression and secretion of the chemokines CCL2 and CXCL12 from prostate stromal WPMY-1 fibroblasts and monocytic macrophage-like THP-1 cells. In vitro studies demonstrated functional co-operation of tumor-derived CXCL8 with stromal-derived chemokines. CXCL12-induced migration of PC3 cells and CCL2-induced proliferation of prostate cancer cells were dependent upon intrinsic CXCL8 signaling within the prostate cancer cells. For example, in co-culture experiments, CXCL12/CXCR4 signaling but not CCL2/CCR2 signaling supported fibroblast-mediated migration of PC3 cells while CXCL12/CXCR4 and CCL2/CCR2 signaling underpinned monocyte-enhanced migration of PC3 cells. Combined inhibition of both CXCL8 and CXCL12 signaling was more effective in inhibiting fibroblast-promoted cell motility while repression of CXCL8 attenuated CCL2-promoted proliferation of prostate cancer cells. We conclude that tumor-derived CXCL8 signaling from PTEN-deficient tumor cells increases the sensitivity and responsiveness of CaP cells to stromal chemokines by concurrently upregulating receptor expression in cancer cells and inducing stromal chemokine synthesis. Combined chemokine targeting may be required to inhibit their multi-faceted actions in promoting the invasion and proliferation of aggressive CaP.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Oncology

Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program

Mark Lawler, Anna Gavin, Manuel Salto-Tellez, Richard D. Kennedy, Sandra Van Schaeybroeck, Richard H. Wilson, Denis Paul Harkin, Margaret Grayson, Ruth E. Boyd, Peter W. Hamilton, Darragh G. McArt, Jacqueline James, Tracy Robson, Robert D. Ladner, Kevin M. Prise, Joe M. O'Sullivan, Timothy Harrison, Liam Murray, Patrick G. Johnston, David J. Waugh

CANCER (2016)

Article Oncology

Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer

Philip D. Dunne, Darragh G. McArt, Conor A. Bradley, Paul G. O'Reilly, Helen L. Barrett, Robert Cummins, Tony O'Grady, Ken Arthur, Maurice B. Loughrey, Wendy L. Allen, Simon S. McDade, David J. Waugh, Peter W. Hamilton, Daniel B. Longley, Elaine W. Kay, Patrick G. Johnston, Mark Lawler, Manuel Salto-Tellez, Sandra Van Schaeybroeck

CLINICAL CANCER RESEARCH (2016)

Editorial Material Urology & Nephrology

Expanding the Armamentarium for Castrate-resistant Prostate Cancer

David J. J. Waugh

EUROPEAN UROLOGY (2017)

Article Urology & Nephrology

Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology

Steven M. Walker, Laura A. Knight, Andrena M. McCavigan, Gemma E. Logan, Viktor Berge, Amir Sherif, Hardev Pandha, Anne Y. Warren, Catherine Davidson, Adam Uprichard, Jaine K. Blayney, Bethanie Price, Gera L. Jellema, Christopher J. Steele, Aud Svindland, Simon S. McDade, Christopher G. Eden, Chris Foster, Ian G. Mills, David E. Neal, Malcolm D. Mason, Elaine W. Kay, David J. Waugh, D. Paul Harkin, R. William Watson, Noel W. Clarke, Richard D. Kennedy

EUROPEAN UROLOGY (2017)

Article Cell Biology

Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists

Christopher McCann, Nyree Crawford, Joanna Majkut, Caitriona Holohan, Chris W. D. Armstrong, Pamela J. Maxwell, Chee Wee Ong, Melissa J. LaBonte, Simon S. McDade, David J. Waugh, Daniel B. Longley

CELL DEATH & DISEASE (2018)

Article Oncology

ACE: A Workbench Using Evolutionary Genetic Algorithms for Analyzing Association in TCGA

Alan R. Gilmore, Matthew Alderdice, Kienan Savage, Paul G. O'Reilly, Aideen C. Roddy, Philip D. Dunne, Mark Lawler, Simon S. McDade, David J. Waugh, Darragh G. McArt

CANCER RESEARCH (2019)

Article Cell Biology

Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer

Diletta Di Mitri, Michela Mirenda, Jelena Vasilevska, Arianna Calcinotto, Nicolas Delaleu, Ajinkya Revandkar, Veronica Gil, Gunther Boysen, Marco Losa, Simone Mosole, Emiliano Pasquini, Rocco D'Antuono, Michela Masetti, Elena Zagato, Giovanna Chiorino, Paola Ostano, Andrea Rinaldi, Letizia Gnetti, Mariona Graupera, Ana Raquel Martins Figueiredo Fonseca, Ricardo Pereira Mestre, David Waugh, Simon Barry, Johann De Bono, Andrea Alimonti

CELL REPORTS (2019)

Article Oncology

ATM Kinase Inhibition Preferentially Sensitises PTEN-Deficient Prostate Tumour Cells to Ionising Radiation

Conor Hanna, Victoria L. Dunne, Steven M. Walker, Karl T. Butterworth, Nuala McCabe, David J. J. Waugh, Richard D. Kennedy, Kevin M. Prise

Summary: Prostate cancer is the most frequently diagnosed cancer in men, with the role of the PTEN gene being complex but important in its treatment. Studies suggest that in the absence of PTEN, combined treatment using radiotherapy and the ATM inhibitor KU-60019 has a greater therapeutic effect.

CANCERS (2021)

Article Multidisciplinary Sciences

Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells

Francesca Amoroso, Kimberley Glass, Reema Singh, Francisco Liberal, Rebecca E. Steele, Sarah Maguire, Rohinton Tarapore, Joshua E. Allen, Sandra Van Schaeybroeck, Karl T. Butterworth, Kevin Prise, Joe M. O'Sullivan, Suneil Jain, David J. Waugh, Ian G. Mills

Summary: The study demonstrated that ONC201 can enhance the radiation response of prostate cancer cells by suppressing the expression of cell cycle and DNA repair factors.

SCIENTIFIC REPORTS (2021)

Article Medicine, General & Internal

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

Blossom Mak, Hui-Ming Lin, Edmond M. Kwan, Heidi Fettke, Ben Tran, Ian D. Davis, Kate Mahon, Martin R. Stockler, Karen Briscoe, Gavin Marx, Alison Zhang, Megan Crumbaker, Winston Tan, Kevin Huynh, Thomas G. Meikle, Natalie A. Mellett, Andrew J. Hoy, Pan Du, Jianjun Yu, Shidong Jia, Anthony M. Joshua, David J. Waugh, Lisa M. Butler, Manish Kohli, Peter J. Meikle, Arun A. Azad, Lisa G. Horvath

Summary: This study assessed the association between circulating lipids, somatic genetic aberrations, and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). The results revealed that certain genetic aberrations were associated with elevated circulating sphingolipids, and patients with both genetic and lipid abnormalities had worse prognosis. These findings may have implications for the selection of metabolic therapies.

BMC MEDICINE (2022)

Article Oncology

Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers

Pamela J. Maxwell, Melanie McKechnie, Christopher W. Armstrong, Judith M. Manley, Chee Wee Ong, Jenny Worthington, Ian G. Mills, Daniel B. Longley, James P. Quigley, Amina Zoubeidi, Johann S. de Bono, Elena Deryugina, Melissa J. LaBonte, David J. J. Waugh

Summary: Inhibiting androgen signaling using androgen signaling inhibitors is the primary treatment for castrate-resistant prostate cancer. However, acquired resistance to androgen receptor-targeted therapy is a major challenge. This study found that enzalutamide induces hypoxia and angiogenesis, which may contribute to relapse. Concurrent inhibition of two hypoxia-induced factors can prolong tumor sensitivity to enzalutamide.

MOLECULAR CANCER RESEARCH (2022)

Article Genetics & Heredity

Prostate cancer heterogeneity assessment with multi-regional sampling and alignment-free methods

Ross G. Murphy, Aideen C. Roddy, Shambhavi Srivastava, Esther Baena, David J. Waugh, Joe M. O'Sullivan, Darragh G. McArt, Suneil Jain, Melissa J. LaBonte

NAR GENOMICS AND BIOINFORMATICS (2020)

Article Biochemistry & Molecular Biology

Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma

Chris W. D. Armstrong, Jonathan A. Coulter, Chee Wee Ong, Pamela J. Maxwell, Steven Walker, Karl T. Butterworth, Oksana Lyubomska, Silvia Berlingeri, Rebecca Gallagher, Joe M. O'Sullivan, Suneil Jain, Ian G. Mills, Kevin M. Prise, Robert G. Bristow, Melissa J. LaBonte, David J. J. Waugh

NAR CANCER (2020)

Review Oncology

Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer

Semini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, Gerhardt Attard, Kim N. Chi, Charlotte L. Bevan, Aki Shibakawa, Maarten J. IJzerman, Bram De Laere, Martijn Lolkema, David Lorente, Jun Luo, Niven Mehra, David Olmos, Howard Scher, Howard Soule, Nikolas H. Stoecklein, Leon W. M. M. Terstappen, David Waugh, Johann S. de Bono

EUROPEAN UROLOGY ONCOLOGY (2018)

Article Oncology

Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy

S. Jain, C. A. Lyons, S. M. Walker, S. McQuaid, S. O. Hynes, D. M. Mitchell, B. Pang, G. E. Logan, A. M. McCavigan, D. O'Rourke, D. G. McArt, S. S. McDade, I. G. Mills, K. M. Prise, L. A. Knight, C. J. Steele, P. W. Medlow, V. Berge, B. Katz, D. A. Loblaw, D. P. Harkin, J. A. James, J. M. O'Sullivan, R. D. Kennedy, D. J. Waugh

ANNALS OF ONCOLOGY (2018)

暂无数据